Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)
Nicholas Lintzeris, Llewellyn Mills, Anastasia Suraev, et al.
Harm Reduction Journal (2020) Vol. 17, Iss. 1
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9472-9472
Open Access | Times Cited: 194
Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process
Arun Bhaskar, Alan Bell, Michael Boivin, et al.
Journal of Cannabis Research (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 115
Cannabidiol - a friend or a foe?
Bianca-Maria Tihăuan, Tatiana Onisei, Walter Slootweg, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107036-107036
Open Access | Times Cited: 1
Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance
Thomas R. Arkell, Frederick Vinckenbosch, Richard C. Kevin, et al.
JAMA (2020) Vol. 324, Iss. 21, pp. 2177-2177
Open Access | Times Cited: 134
Access to cannabidiol without a prescription: A cross-country comparison and analysis
Iain S. McGregor, Elizabeth A. Cairns, Sarah V. Abelev, et al.
International Journal of Drug Policy (2020) Vol. 85, pp. 102935-102935
Open Access | Times Cited: 80
Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic
Lucile Rapin, Rihab Gamaoun, Cynthia El Hage, et al.
Journal of Cannabis Research (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 65
Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)
Nicholas Lintzeris, Llewellyn Mills, Sarah V. Abelev, et al.
Harm Reduction Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 37
Prescribing medicinal cannabis
Jonathon C. Arnold, Tamara Nation, Iain S. McGregor
Australian Prescriber (2020) Vol. 43, Iss. 5, pp. 152-159
Open Access | Times Cited: 59
Real World Evidence in Medical Cannabis Research
R. Banerjee, Simon Erridge, Oliver Salazar, et al.
Therapeutic Innovation & Regulatory Science (2021) Vol. 56, Iss. 1, pp. 8-14
Open Access | Times Cited: 49
Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial
Timna Naftali, Lihi Bar‐Lev Schleider, Shlomo Almog, et al.
Journal of Crohn s and Colitis (2021) Vol. 15, Iss. 11, pp. 1799-1806
Closed Access | Times Cited: 46
Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations
Lyndsey L. Anderson, Maia G. Etchart, Dilara Bahceci, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 40
Citalopram and Cannabidiol
Lyndsey L. Anderson, Peter T. Doohan, Lachlan Oldfield, et al.
Journal of Clinical Psychopharmacology (2021) Vol. 41, Iss. 5, pp. 525-533
Closed Access | Times Cited: 39
Medical cannabis and driving
Thomas R. Arkell, Danielle McCartney, Iain S. McGregor
Australian Journal of General Practice (2021) Vol. 50, Iss. 6, pp. 357-362
Open Access | Times Cited: 32
Cannabinoids, Insomnia, and Other Sleep Disorders
Isobel Lavender, Iain S. McGregor, Anastasia Suraev, et al.
CHEST Journal (2022) Vol. 162, Iss. 2, pp. 452-465
Closed Access | Times Cited: 27
Medical cannabis use in Thailand after its legalization: a respondent-driven sample survey
Sawitri Assanangkornchai, Kanittha Thaikla, Muhammadfahmee Talek, et al.
PeerJ (2022) Vol. 10, pp. e12809-e12809
Open Access | Times Cited: 25
Routes of administration, reasons for use, and approved indications of medical cannabis in oncology: a scoping review
Billy Vinette, José Côté, Ali El-Akhras, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 24
Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition
Llewellyn Mills, Nicholas Lintzeris, Michael O’Malley, et al.
Drug and Alcohol Review (2022) Vol. 41, Iss. 5, pp. 1095-1108
Open Access | Times Cited: 23
The evolving culture of medical cannabis in Canada for the management of chronic pain
Hance Clarke, Mary‐Ann Fitzcharles
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
Available but inaccessible: patient experiences during the first 2 years of a primary care-based medical cannabis program at an academic medical center
Eloise W. Freitag, Yuval Zolotov, Jayabhargav Annam, et al.
Harm Reduction Journal (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 4
Patients’ Perceptions of the Efficacy, Safety, and Quality of the Evidence of Medicinal Cannabis: A Survey of Australian Cancer Patients
Elizabeth A. Fradgley, Ben Britton, Jennifer Martin, et al.
Asia-Pacific Journal of Clinical Oncology (2025)
Open Access
The use of medicinal marijuana for treating Cerebral Palsy: a literature review
Daniel J. McDonough, James P. Charles, T. Claye Shaw
F1000Research (2025) Vol. 13, pp. 825-825
Open Access
Medicinal Cannabis and Consumer Vulnerability in Australia: A Nexus of Policy and Market Factors
Katrina Gething, Daniel Erku, Paul Scuffham
Health Expectations (2025) Vol. 28, Iss. 1
Open Access
Persistent behavioural consequences of chronic adolescent cannabidiol (CBD) in a mouse model with increased susceptibility to Δ9-tetrahydrocannabinol and schizophrenia
Gabriela Visini, Rose Chesworth, Tim Karl
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111306-111306
Closed Access
Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey
Thomas R. Arkell, Nicholas Lintzeris, Llewellyn Mills, et al.
Accident Analysis & Prevention (2020) Vol. 148, pp. 105784-105784
Open Access | Times Cited: 34
The endocannabinoid system – current implications for drug development
Christopher J. Fowler
Journal of Internal Medicine (2020) Vol. 290, Iss. 1, pp. 2-26
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top